Monitor the resolution of the Magnus Medical patent dispute, as an unfavorable outcome could impact the commercialization of the newly cleared accelerated treatment protocol. The company's heavy reliance on a single customer (significant portion of revenue) represents a concentration risk that investors should track in future quarters.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $13.55entry
- T+1 · 7mo ago 0.00%α −1.02% · $13.55
- T+5 · 7mo ago 0.00%α −1.08% · $13.55
- T+20 · 6mo ago +24.28%α +19.37% · $16.84
- T+60 · 4mo ago +11.66%α +4.76% · $15.13
Price Chart
How similar events traded
Executive Summary
Brainsway's 20-F filing for 2025 shows strong financial growth with a 27% revenue increase to $52.2 million and net income of $7.6 million, driven by U.S. market expansion and new FDA clearances. The company's strategic investments in MSOs and Neurolief, along with a significant $20 million private placement, position it for continued growth, although its reliance on a single large customer and ongoing patent litigation with Magnus Medical present notable risks.
Key Facts
- Revenue increased 27.3% YoY to $52.2 million for 2025, with net income of $7.6 million
- U.S. revenue grew 33% to $44.2 million, now representing 85% of total revenue
- Received FDA clearance for adolescent MDD treatment (ages 15-21) and accelerated treatment protocol
- Completed $20 million private placement with Valor in November 2024
- Invested $9.8 million in MSOs (Axis, Tangient, Stella) and $11 million in Neurolief
- Faced patent infringement claim from Magnus Medical regarding accelerated TMS protocol
Financial Impact
Revenue of $52.2 million (+27.3% YoY) and net income of $7.6 million (+162% YoY)
Risk Factors
- Patent infringement lawsuit from Magnus Medical
- High customer concentration risk with a single customer
- Geopolitical risks from operations in Israel
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001171843-26-002568 |
| Exhibit: exh_23.htm | 0001171843-26-002568 |
| Exhibit: exh_424.htm | 0001171843-26-002568 |
| Exhibit: exh_421.htm | 0001171843-26-002568 |
| Exhibit: exh_121.htm | 0001171843-26-002568 |
| Exhibit: exh_122.htm | 0001171843-26-002568 |
| Exhibit: exh_151.htm | 0001171843-26-002568 |
| Exhibit: exh_13.htm | 0001171843-26-002568 |
| Exhibit: exh_8.htm | 0001171843-26-002568 |
| Document: 0001171843-26-002568-index-headers.html | 0001171843-26-002568 |
| Document: 0001171843-26-002568-index.html | 0001171843-26-002568 |
| Document: 0001171843-26-002568.txt | 0001171843-26-002568 |
Track record
5 reports on BRSYF
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +24.28% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Jun 9, 202622w ago 6-K Bullish 7/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.24% vs SPY
- May 18, 202626w ago 6-K Neutral 4/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −15.01% vs SPY
- May 13, 202626w ago 6-K Bullish 8/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.59% vs SPY
- Apr 20, 202630w ago 20-F Bullish 7/10 Viewing Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +4.76% vs SPY
- Apr 15, 202630w ago 6-K Bullish 7/10 Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +3.52% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers